EMA OKs Sublingual Formulation for Opioid Dependence

admin
1 Min Read

The European Medicines Agency has recommended marketing authorization for a new hybrid formulation of buprenorphine for opioid drug dependence treatment. Buprenorphine Neuraxpharm, a sublingual film, is intended for use in adults and adolescents 15 years and older. It should be part of a comprehensive treatment plan. This new hybrid medicine is similar to Subutex but has differences in strength and form. The drug is a partial opioid agonist/antagonist and should be prescribed by a doctor experienced in addiction treatment. Common side effects include headache, nausea, and abdominal pain. Buprenorphine Neuraxpharm will be available in multiple strengths once marketing authorization is granted.

Source link

Share This Article
error: Content is protected !!